EP1641354A1 - Use of isomalt (mixture of 1,6 gps and 1,1 gpm) as a prebiotic for the production of a medicament used for the treatment of intestinal diseases, among other things - Google Patents

Abstract

The invention relates to a novel use of a mixture of 6-O-alpha-D-glucopyranosyl-D-sorbitol and 1-O-alpha-D-glucopyranosyl-D-mannitol as a bifidogenic prebiotic optionally containing a probiotic, to be used as or for producing a food item, semi-luxury food, fodder, or a medicament. Said medicament is used for the treatment and/or prevention of intestinal diseases such as chronic inflammatory intestinal diseases, intestinal cancer, bacterial intestinal infections, among other things.

Description

USE OF ISOMALT (MIX OF 1, 6 GPS AND 1, 1. GPM) AS A PREBIOTIC AND A. FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR TREATING COLONAL DISEASES

The present invention relates to the use of a mixture of 6-O-α-D-glucopyranosyl-D-sorbitol (1,6-GPS) and 1-O-α-D-5 glucopyranosyl-D-mannitol (1,1 -GPM ) as a prebiotic and / or butyrate-providing, partially digestible and intestinal health-promoting carbohydrate in food, luxury foods, feed and / or medicines.

Food, luxury foods and animal feed serve primarily to

10 nutrition and well-being of human and animal consumers. In addition to these two aspects, food and luxury foods are increasingly expected to have a health-promoting function. Food and luxury foods should on the one hand maintain and promote health, and on the other hand harmful influences

Fend off 15 and act prophylactically against diseases if necessary. Such health-promoting foods and stimulants are intended to have their effect primarily in the digestive tract. In the anterior digestive tract, the absorbed nutrients are broken down and partially absorbed. Not

20 digestible carbohydrates get into the large intestine and are available there for the microbial intestinal flora. This intestinal flora includes bacteria such as Bacteroides, Eubacterium, Bifidobacte um, Lactobacillus, Atopobium and Fusobacterium. In addition there are Escherichia coli and optionally pathogenic microorganisms such as

25 clostridia, staphylococci or other Enterobacteriaceen. Lactobacteria, especially bifidobacteria, are known to have health-promoting properties. They produce high levels of short chain organic acids and inhibitors that limit the growth and activity of harmful bacteria,

30 which form unwanted enzymes such as ß-glucosidases, ß-glucuronidases or azoreductases. The importance of some undesirable bacterial enzymes such as ß-glucosidases lies in that Formation, activation and release of toxic, carcinogenic and co-carcinogenic compounds from the body's own and exogenous substances. Bacterial ß-glucosidase releases toxic aglycones from glycosides, for example. By inhibiting harmful bacteria and thus inhibiting the activity of bacterial enzymes such as ß-glucosidase, the production of endotoxins and carcinogenic compounds is restricted and the excretion of xenobiotics is improved. Another positive property of the health-promoting intestinal flora includes immunomodulatory effects and stimulation of the immune function. By inhibiting harmful and pathogenic bacteria, lactobacteria, in particular bifidobacteria, also have a protective and preventive effect against intestinal infections, in particular bacterial diarrhea.

Short-chain fatty acids such as butyric acid (butyrate) are fermentatively formed by saccharolytic bacteria in the large intestine, in particular from undigested carbohydrates. Butyric acid is the dominant source of energy for the epithelial cells in the colon, influences cellular proliferation and differentiation and plays a central role as a growth factor for a healthy intestinal epithelium and in maintaining the mucosal barrier in the colon. Short-chain fatty acids such as butyric acid or its salts, butyrate, contribute to the detoxification of possible mutagenic metabolites in the large intestine and counteract oxidative stress, for example by inducing gene expression of protective proteins such as intestinal glutathione-S-transferase or by inhibiting ornithine. carboxylase. Furthermore, short-chain fatty acids such as butyric acid have a controlling effect on the induction of specific genes and the modification of proteins of cell cycle regulation, antibacterial peptides and signal cascades. High concentrations of butyric acid in the large intestine, especially in the rear areas of the large intestine, support a healthy intestinal environment and a healthy intestinal epithelium, improve symptoms of ulcerative inflammation of the colon and are Protective in colon carcinogenesis, which means reducing the risk of colon cancer.

It is desirable to promote the intestinal flora, which has a positive effect on human or animal health, and in addition to achieve a production of large amounts of butyric acid, in particular also in the rear sections of the large intestine. This can be achieved by adding suitable substrates to improve the living conditions for the healthy intestinal flora and substrates for the microbial formation of butyric acid, also in the rear areas of the large intestine.

Substances or mixtures of substances which selectively promote the growth and / or the activity of specific health-promoting intestinal bacteria, in particular bifidobacteria and lactobacilli, as constituents of foods or luxury foods are termed prebiotics. Prebiotics promote the growth and / or activity of health-promoting intestinal bacteria and are usually carbohydrates that are not digestible by enzymes in the gastrointestinal tract.

From Cummings et al. (Am. J. Clin. Nutr. 73 (2001), 415-420 it is known that prebiotics can be longer-chain carbohydrates, for example inulin or fructooligosaccharides. Kümmel & Brokx (Cereal Foods World 46 (2001), 424-429) describe lactit in the prebiotic, but there are also known long-chain carbohydrates that do not stimulate the growth of bifidobacteria, including higher-molecular plant hemicelluloses such as xylan from larch, wheat and oats or polysaccharides of marine origin such as laminarin and alginate are primarily metabolized by the genus Bacteroides.

Not all saccharides known as prebiotics are used to deliver butyrate, and if they do, only in the front large intestine. pass. Known prebiotics such as fructooligosaccharides that reach the colon are fermented there quite quickly and completely. The short-chain fatty acids formed in this way are quickly and almost completely absorbed by the intestinal epithelial cells at the point at which they arise. For delivery of butyrate to the rear intestinal tract, however, it is necessary that the saccharides are fermented more slowly so that substrate can also reach the intestinal areas lying behind and are available for microbial butyrate formation. A very rapid fermentation of known prebiotics can mean, among other things, a higher risk for laxative effects and other gastrointestinal ailments.

Furthermore, known prebiotics such as inulin and oligofructose are also disadvantageously characterized in that when they are broken down, other short-chain fatty acids, in particular acetic acid, are formed predominantly by the intestinal microflora and therefore only provide butyric acids to a very small extent. The known prebiotics such as fructooligosaccharides are also disadvantageous in that their technological processability in food production leaves something to be desired. A lack of water solubility, for example in the case of longer-chain carbohydrates such as resistant starch, their low acid stability and their reactivity as partially reducing oligosaccharides contribute to their limited applicability. This is especially true when used in products that have a low pH. The known prebiotics are further disadvantageous in that they are fermented comparatively quickly and / or lead to only a slight formation of butyric acid and are therefore only slightly butyrogenic.

The present invention is therefore based on the technical problem of providing substances or substance mixtures which take on prebiotic functions in food, luxury foods, feeds and pharmaceuticals and at the same time support the formation of butyric acid can and thereby overcome the aforementioned disadvantages, in particular with the best possible processability, advantageous nutritional parameters and good tolerability, act as bifidogenic prebiotics and serve as a butyrate-non-butyrenic substrate.

The present invention solves the technical problem on which it is based by providing a use of mixtures of 1,6-GPS and 1,1-GPM in food, luxury foods, feed and pharmaceuticals as a prebiotic, in particular a bifidogenic prebiotic and / or as a fermentable substrate, in particular as a non-butyrate and at the same time slower fermentable substrate, with good technological processability.

The present invention is based inter alia on the fact that the mixture of 1,6-GPS and 1,1-GPM. used in food, luxury foods, feed and pharmaceuticals after consumption in the gastrointestinal tract of human or animal consumers has prebiotic, in particular bifidogenic activity and / or serves as a substrate for the formation of butyric acid.

The investigations of the mixture used according to the invention surprisingly showed that consumption of a mixture of 1,6-GPS and 1,1 -GPM leads to an increase in good and health-promoting bacteria, in particular bifidobacteria in the intestinal tract of the consumer, which can be demonstrated, for example, by an increase in bifidobacteria in the stool flora. In addition, the mixture used according to the invention is characterized in that consumption by the consumer also leads to an increase in the proportion of bifidobacteria in the total flora.

Furthermore, it emerged from the investigations that consumption of the mixture used according to the invention also leads to a favorable influences the activity of the microflora, in particular by lowering the activity of the bacterial enzyme β-glucosidase, which leads to the formation of toxic compounds in the intestine.

It has also proven to be advantageous that the mixture used according to the invention can be consumed by humans in larger quantities, for example of 30 g / d and more, with the daily diet without causing gastrointestinal inconveniences.

The bifidogenic and prebiotic effect of the mixture used according to the invention was surprising, since in older studies in w ^' fro, almost no drop in pH was observed due to bifidobacterial strains with 1,6-GPS or 1,1-GPM and this did not initially indicate a bifidogenic or prebiotic property of isomalt (Kashimura et al, 1991).

In the context of the present invention, however, it has now been shown that bifidobacteria can grow and degrade with isomalt and thereby form short-chain fatty acids. It was also possible to show that the mixture used according to the invention is also suitable as the only preferred carbon and energy source for bifidobacteria.

In this context, “bifidobacteria” or “bifidus flora” refers to a genus of gram-positive, immobile, immobile, sporeless, and anaerobic rod bacteria, in particular of the species B. adolescentis, B. bifidum, B. breve, B. catenulatum, which colonizes the large intestine. B. longum and B. infantis understood. These cleave carbohydrates to form short-chain organic acids, especially acetic acid (acetate) and lactic acid (lactate). This reduces the pH value of the environment and inhibits pathogenic bacteria. Bifidobacteria are bacteria that are particularly desirable for human before health is considered. The beneficial effects of bifidobacteria include the suppression of pathogenic germs, the reduction of the ammonia and lipid concentration in the blood, the regeneration of an intestinal flora damaged by antibiotics, the stimulation of the immune system and an immunomodulatory effect, for example also to support the defense against malignant cells, and the production of vitamins such as B vitamins and folic acid. Bifidobacteria are considered to be important carriers of colonization resistance to pathogenic bacteria and antagonists of putrefactive flora. Through the fermentative production of short-chain fatty acids in the large intestine and inhibitors, they contribute to the inhibition of the growth of harmful bacteria and their activity, for example by inhibiting harmful bacterial enzymes such as β-glucosidase. By inhibiting pathogenic bacteria, bifidobacteria also have a protective and preventive effect against infections, in particular bacterial intestinal infections. By producing short-chain fatty acids in the large intestine, bifidobacteria contribute to the nutrient supply and maintenance of the large intestinal mucosa.

Unlike lactobacilli, for example, bifidobacteria cannot or only to a limited extent be used in foods, i.e. probiotic foods, because of their sensitivity to atmospheric oxygen. By combining probiotic cultures and the mixture used according to the invention as a prebiotic substance, an improved survival of the living bacteria in synbiotic products can be achieved, as well as the stimulation of both supplied and, in particular, endogenously present positive bacteria such as bifidobacteria in the entire intestinal tract.

It was also possible to show that the mixture used according to the invention is also metabolized more slowly by human intestinal flora and leads to higher butyrate production than, for example, the known prebiotic fructans. As a result of the slower fermentation of the mixture used according to the invention compared to known prebiotic substrates and the simultaneous higher formation of butyric acid, the mixture used according to the invention, which is consumed with food, reaches the rear areas of the large intestine to a greater extent and can be used there as an active ingredient, for example for treatment or prevent colon diseases.

The mixture used according to the invention is further characterized by an extremely good technological processability in food, enjoyment and animal feed, also due to its water solubility and acid stability. The acid stability makes the use according to the invention particularly suitable for products which have a low pH.

The use of the mixture mentioned according to the invention is also advantageously distinguished in that it can be used in humans and animals to support and stabilize healthy intestinal flora, to promote healthy intestinal flora metabolism, to maintain healthy intestinal epithelium, to support intestinal health. for the reduction of toxic and damaging intestinal contents, for the prevention and treatment of inflammatory bowel diseases and / or for the prevention of colon cancer and other diseases of the intestinal epithelium. In addition, the mixture can be used for the prevention and control of infectious diseases, in particular also bacterial intestinal infections and diarrheal diseases, and for modulating and supporting the immune system, as a substance with properties of soluble fiber and / or as a substance with prebiotic properties.

These positive effects of the use of the mixture according to the invention on the health of humans and animals are also due to the increase in the quantity and the proportion of Lactobacteria, in particular bifidobacteria in or on the intestinal flora, the inhibition of harmful bacterial enzymes such as β-glucosidase and / or the slower fermentation and at the same time high butyric acid formation due to the intestinal flora.

The mixture used in the use according to the invention advantageously reaches the large intestine, where it then serves as a substrate for the microorganisms present there, such as lactobacteria, in particular bifidobacteria, and is fermented to give short-chain fatty acids. This leads to a stimulation of the bifidobacteria and an increase in both the number of bifidobacteria and the proportion of bifidobacteria in the total flora, and thus a shift in the flora towards a bifidus flora. The short-chain fatty acids produced by the bifidobacteria and inhibitors result in an inhibition of the harmful bacteria and their activity, which in particular also shows a reduction in the activity of the microbial β-glucosidase, which releases toxic and carcinogenic compounds. The mixture according to the invention therefore has bifidogenic and prebiotic properties. The isomalt according to the invention is also fermented comparatively slowly by the human intestinal flora and promotes the saccharolytic microflora. High concentrations of butyric acid in the colon support a healthy intestinal environment, improve symptoms of ulcerative inflammation of the colon and are protective in colon carcinogenesis. Butyric acid serves as a growth factor for a healthy intestinal epithelium and as a substrate for the colon cells and thus counteracts the development and growth of colon carcinomas, among other things. Butyric acid contributes to the detoxification of possible mutagenic metabolites in the colon and counteracts oxidative stress, for example by inducing protective proteins such as intestinal glutathione-S-transferase or by inhibiting ornithine decarboxylase. A healthy intestinal environment prevents negative effects such as diarrhea, Constipation, inflammation and the passage of unwanted substances and bacteria from the intestinal lumen into the body.

The use according to the invention of the mixture used has a positive effect on the health of humans and animals, in particular by increasing the quantity and the proportion of lactobacteria, in particular bifidobacteria in or on the intestinal flora, and the slower fermentation and, at the same time, high butyric acid formation by the saccharolytic intestinal flora , The use according to the invention of the mixture used serves to support and stabilize healthy intestinal flora, to promote healthy intestinal flora metabolism, to maintain healthy intestinal epithelium, to maintain intestinal health, to reduce toxic and harmful intestinal contents, to reduce oxidative stress, prevention and treatment of inflammatory bowel diseases, prevention of colon cancer, especially colon cancer, also in the back of the intestine and other diseases of the intestinal epithelium. In addition, the mixture serves to prevent and combat infectious diseases, especially bacterial intestinal infections, and to modulate and support the immune system.

In connection with the present invention, a “prebiotic” is understood to mean a food, luxury food, feed or pharmaceutical component which selectively controls the growth and / or the activity of specific bacteria in the human or animal digestive tract, in particular bifidobacteria and / or lactobacilli stimulated in such a way that health-promoting effects can be expected. Prebiotics are usually not digestible or difficult to digest.

In connection with the present invention, a “probiotic” is understood to mean a living microbial constituent of a food, luxury food, feed or pharmaceutical, which is stabilized or improved in the microbial composition in the The human or animal consumer’s digestive tract promotes their health. Such probiotic microorganisms that can be used in food, pharmaceuticals or feed are, for example: Bifidobacterium such as the strains B. adolescentis, ß. animalis, B. bifidum, B. longum, B. thermophilum; Enterococcus; Lactobacillus such as the strains Lb. acidophilus, Lb. brevis, Lb. casei, Lb. cellobiosus, Lb. crispatus, Lb. delbrueckii subsp. Bulgaricus, Lb. fermentum, Lb. GG, Lb. johnsonii, Lb. lactis, Lb. plantarum, Lb. reuten, Lb. rhamnosus, Lb. salivarius; Bacillus cereus toyoi; Bacillus cereus; Leuconostoc; Pediococcus acidilactici; Propionibacterium; Streptococcus like the strains S. cremoris, S. infantarius, S. intermedius, S. lactis, S. salivarius subsp. thermophilus (see Füller, J. Appl. Bacteriol. (1989)). Preferred probiotics are bacteria of the genera Lactobacillus and Bifidobacterium.

In connection with the present invention, “synbiotic” is understood to mean a mixture of at least one prebiotic and at least one probiotic, which improves the survival rate and increases the number of health-promoting living microbial organisms in the gastrointestinal tract, the health of human or animal Promotes consumers, especially by selectively stimulating the growth and / or metabolic activity of the microbial organisms.

“Food” or “feed” are understood to mean primarily substances or mixtures of substances in solid, liquid, dissolved or suspended form which serve human or animal nutrition. A stimulant is primarily understood to mean substances or mixtures of substances in solid, liquid, dissolved or suspended form which serve the enjoyment of the human or animal body when consumed. A medicinal product is mainly used for the prophylaxis or therapy of diseases, disorders, injuries or signs of aging in the human or animal body. understood mixtures in solid, liquid, dissolved or suspended form.

In connection with the present invention, “illness” or “illness” is understood to mean a disruption of life processes and / or deficiency states in organs or in the entire organism which brings about a subjectively perceived and / or an objectively ascertainable physical and / or psychological change ,

In connection with the present invention, “active substance” is understood to mean a substance that can produce a biological effect in living organisms or parts thereof. This active ingredient can serve in particular for the prevention, relief, healing or diagnosis of a disease. A “therapeutic agent” is understood to mean a substance which serves for the prevention or prophylaxis, relief or healing of an illness.

In connection with the present invention, “medicament” is understood to mean a preparation of active substances intended for use in humans or animals.

In a preferred embodiment, the invention relates to a use, in which use the mixture of 1,6-GPS and 1,1-GPM is isomalt. In connection with the present invention, isomalt is understood to mean the mixture of 1,6-GPS and 1,1-GPM, also referred to as palatinite, for example a mixture which contains 43 to 57% by weight of 1,6-GPS and 57 to 43 wt .-% 1, 1-GPM, based on the dry matter of the mixture contains.

In a further preferred embodiment of the present invention, the mixture used according to the invention consists of 1,6-GPS and 1, 1 -GPM, essentially consists of or contains them. The mixture is preferably a 1,6-GPS-enriched or a 1,1-GPM-enriched mixture or contains this, so as described in DE 195 32 396 C2, which is completely included in the disclosure content of the present teaching with regard to the production and composition of the mixtures enriched in 1,6-GPS and 1,1-GPM.

In a further preferred embodiment of the present invention, the mixture of 1,6-GPS and 1,1-GPM used in a food, luxury food, feed or pharmaceutical according to the invention is the only prebiotic and / or the only butyrogenic substrate and / or as the only sweetener in the food, edible, feed or pharmaceutical. Of course, however, it is also provided that the mixture of 1,6-GPS and 1, 1-GPM contains further substances or substance mixtures, for example 1,1-GPS (1-O-α-D-glucopyranosyl-D-sorbitol). In addition to 1,6-GPS and 1,1 -GPM, the mixture used in accordance with the invention can also contain mannitol, sorbitol, hydrogenated or non-hydrogenated oligosaccharides.

In a further preferred embodiment it is provided that the mixture of 1,6-GPS and 1,1-GPM used according to the invention as a prebiotic and / or as a butyrogenic substrate in the target products, that is to say the food, luxury food, feed or medicinal product. agents, is used together with at least one further soluble and / or at least one insoluble, fermentable or non-fermentable dietary fiber and / or non-digestible carbohydrate.

The following are provided as soluble and / or insoluble dietary fibers: polydextrose; Fructoooligosaccharides with short and long saccharide chains, for example ß (2 → 1) fructans, for example from extraction from chicory root and possible subsequent partial hydrolysis, or from transfructosylation of sucrose; Galacto-oligosaccharides and transgalactosylated oligosaccharides, for example by transgalactosylation of lactose such as 6 'galactosyllactose (with Aspergillus oryzae β-galactosidase) or 4' Galactosyl lactose (with Cryptococcus laurentii or Bacillus circulans ß-galactosidase); partially hydrolyzed guar gum, such as "Sunfibre" or "Benefibre";lactulose;lactitol;maltitol;sorbitol;mannitol;xylitol;Erythritol; hydrogenated starch hydrolysates; Xylo-oligosaccharides, for example with ß (1 → 4) linked xylose units, for example from the enzymatic hydrolysis of xylan; Meneba xylo gold or xyloarabane; lactosucrose; Malto-oligosaccharides, such as "Fibersol-2" from Matsutani, and isomalto-oligosaccharides, such as from Showa Sangyoi, for example from the transgalactosylation of maltose; for example linked to α (1 → 4) glucose via α (1 → 6) -glucose; gentio-oligosaccharides, for example oligosaccharides with β (1 → 6) linkages; pyrodextrin, for example from the pyrolysis of corn or potato starch; glucosyl-sucrose, such as "coupling even" from Hayashibara; Soybean oligosaccharides, such as mixtures of raffinose (Gal-Glc-Frc) and stachyose (Gal-Gal-Glc-Frc) from the extraction of soybean whey; Chito oligosaccharides or chitosan oligosaccharides; Di- and oligosaccharides from honey, pectins and from pectins, including oligosaccharides obtained by partial hydrolysis; condensed oligosaccharides, for example from the condensation of saccharides, also saccharides modified by enzymatic modification and hydrogenation; di- and oligosaccharides obtained by caramelization of saccharides; Galactomannan oligosaccharides, carbohydrates with other monosaccharides; Obtain carbohydrates with other monosaccharides, di- and oligosaccharides, for example also by partial hydrolysis or oxidation or other modification of di- and oligosaccharides. According to the invention, preference is given to using at least one fiber and / or indigestible carbohydrate which contains a fructo-oligosaccharide, polydextrose, inulin, a galacto-oligosaccharide, lactulose, lactitol, a xylo-oligosaccharide, lacto-sucrose, a malto-oligosaccharide Oligosaccharide, a gentio-oligosaccharide, glucosyl-sucrose, a soybean-oligosaccharide, a chito-oligosaccharide, a chitosan-oligosaccharide, a pectin, a condensed oligosaccharide, a caramel product Galactomannan oligosaccharide, an oligosaccharide containing fucose, an oligosaccharide containing fucose derivatives, modified starch, partially hydrolyzed guar gum, maltitol, sorbitol, mannitol, xylitol, erythritol, hydrogenated starch hydrolyzate, pyrodextrin, or by partial hydrolyzation, hydrolysis, enzymes, by hydrolysis, hydrolysis, hydrolysis, by partial hydrolysis, by hydrolysis, by hydrolysis, by hydrolysis, by hydrolysis, by hydrolysis, hydrolysis, by hydrolysis, by partial hydrolysis chemical or other modification of saccharides obtained variant. Resistant starch such as "Neo-Amylose" or "Actistar", fibers from oats, wheat, vegetables, for example tomato or pea, fruits, for example apple, various berries, fruits of the carob tree, fibers from sugar beet, such as " Fibrex "from Danisco, from fruits of the carob tree, such as" Caromax "from Nutrinova, or cellulose or Vitacel from Rethenmaier.

In a further preferred embodiment of the present invention, the mixture of 1,6-GPS and 1,1-GPM used according to the invention, optionally in a mixture with one of the aforementioned fibers, in particular substances with a prebiotic and / or butyrogenic effect, additionally contains at least one probiotic, for example Bacteria of the genus Lactobacillus and / or Bifidobacterium, for example Bacillus cereus toyoi; Bacillus cereus; Bifidobacterium as the strains: B. adolescentis, B. animalis, B. bifidum B. longum, B. thermophilum; Enterococcus; Lactobacillus such as the strains Lb. acidophilus, Lb. brevis, Lb. casei, Lb.cellobiosus, Lb. crispatus, Lb. delbrueckii subsp. Bulgaricus, Lb. fermentum, Lb. GG, Lb. johnsonii, Lb. lactis, Lb. plantarum, Lb. reuteri, Lb. rhamnusus, Lb. salivarius; Leuconostoc; Pediococcus acidilactici; Propionibacterium; Streptococcus like the strains S. cremoris, S. infantarius, S. intermedius, S. lactis, S. salivarius subsp. thermophilus (see Füller, J. Appl. Bacteriol. (1989)), in particular bacteria of the genus Lactobacillus and / or Bifidobacterium.

According to the invention, the mixture of 1,6-GPS and 1,1-GPM is therefore used in a particularly preferred embodiment as part of a synbiotic. By the provided according to the invention A combination of a probiotic and the mixture used according to the invention, in particular isomalt, as a prebiotic can advantageously achieve better survival of the probiotic bacteria during passage through the upper gastrointestinal tract and an improved success rate in the settlement of the probiotic bacteria in the intestinal tract, in particular the large intestine become. In addition, the prebiotic mixture used according to the invention increases the growth and activity of both the exogenously supplied probiotic and the endogenously present bacteria, in particular bifidobacteria.

In a further preferred embodiment of the present invention, the mixture of 1,6-GPS and 1, 1-GPM used according to the invention in a food, luxury food, feed or pharmaceutical is preferably used as a prebiotic, in particular bifidogenic prebiotic and / or as butyrogenic, slowly fermentable substrate used. In addition, a higher concentration of butyric acid (butyrate) is obtained by activating saccharolytic bacteria in the large intestine due to the butyrogenic and slower fermentation of the mixture used according to the invention, in particular isomalt.

Of course, this mixture can contain other additives and auxiliaries such as preservatives, colors, flavors, aromas, food-compatible acids, intensive sweeteners, emulsifiers, lubricants and release agents, medicinal substances, vitamins, coenzymes, minerals or trace elements.

In a further preferred embodiment of the present invention, the mixture used according to the invention is used in foods such as milk products and milk products, such as cheese, butter, yoghurt, drinking yoghurt, kefir, quark, sour milk, buttermilk, cream, condensed milk -, dry milk, whey, milk sugar, milk protein, milk mix, milk semi-fat, whey mix, or milk fat products or preparations; Bakery products, in particular bread, rolls, croissants including biscuits or pastries including long-life baked goods, biscuit products or waffles; Spreads, margarine products or shortenings; Instant products and broths; Fruit products or fruit preparations such as jams, jams, jellies, gelling sugar, canned fruit, fruit pulps, fruit pulp, fruit juices, fruit concentrates, fruit nectar or fruit powder; Vegetable products or preparations such as canned vegetables, vegetable juices or vegetable pulp; Spice mixes; Muesli or muesli mixtures, as well as products containing prepared muesli; non-alcoholic beverages such as athletic beverages and lemonades, beverage bases and beverage powder; Confectionery such as chocolate, hard caramels, soft caramels, chewing gum, dragees, fondant products, jelly products, licorice, foam sugar products, flakes, dragees, compressed products, candied fruit, brittle, nougat products, ice confectionery, marzipan, cereal bars, and ice cream or alcoholic beverages non-alcoholic sweet drinks etc. and / or enteral diets.

Another preferred object of the present invention is the use of the mixture used according to the invention as an active ingredient, in particular as a therapeutic active ingredient, in particular in medicaments, medicament-like preparations, foodstuffs, foodstuffs and / or luxury foods and as an additive in animal feedstuffs for the treatment of diseases , In particular, these are pharmaceutical compositions, a medicament which contains the isomalt according to the invention, and the use of the isomalt according to the invention for the production of such medicaments. In one variant, the mixture used according to the invention is used as an active ingredient for the treatment of intestinal diseases.

In further variants of the invention, the mixture used according to the invention is used as an active ingredient for restoration and stabilization. To improve healthy intestinal flora, to restore and / or promote healthy intestinal flora metabolism, to restore and / or promote healthy intestinal epithelium, to restore and / or promote intestinal health, to reduce oxidative stress, to reduce toxic and damaging intestinal contents Prevention and / or treatment of inflammatory bowel diseases, for the prophylaxis of colon cancer, in particular colon cancer, for the prophylaxis of infectious diseases, for the prophylaxis of bacterial intestinal infections and / or for the modulation and strengthening of the immune system.

In addition, the mixture used according to the invention is used in particular in animal feed, both in the small animal and in the large livestock sector.

The invention also relates to the use of the mixture used according to the invention as an active ingredient, optionally together with at least one of the abovementioned additives and auxiliaries, such as further prebiotics or indigestible carbohydrates, in particular fiber or substances with a fiber-like effect, or probiotics, in a medicament or for the preparation a medicament for combating and / or prophylaxis of disease states, disorders, injuries or signs of aging, in particular also diseases and disorders of the gastrointestinal tract, the human or animal body.

The mixture used according to the invention is used alone or preferably together with other substances in the food, luxury foods, feed or pharmaceuticals in solid, for example crystalline but also amorphous, ground or liquid, in particular suspended or dissolved form. Suitable suspension or solvents are food-compatible solvents, in particular water, alcohols and mixtures thereof. Further advantageous refinements of the present invention result from the subclaims.

The invention is explained in more detail with the aid of the following examples and associated figures.

FIG. 1 shows a comparison of the total activity of microbial β-glucosidase in stool samples from subjects with isomalt consumption or with placebo consumption.

FIG. 2 shows breakdown rates of fructooligosaccharides (FOS) and isomalt in the in-fermentation with human intestinal bacteria.

FIG. 3 shows in the form of a histogram the formation of butyrate in the in-yro fermentation of isomalt and FOS.

Example 1: Isomalt effect on humans

To demonstrate the fermentative effects of isomalt on the intestinal environment in humans and the influence of isomalt on human intestinal microflora, a human intervention study was carried out with a collective of 20 healthy volunteers in a double-blind, placebo-controlled crossover design. Each of the subjects received either 30 g / day isomalt as verum or sucrose as placebo in the two 4-week test phases. During the two test phases, the test subjects received standardized basic food. The test substances were taken several times a day in the form of pastries, jams, chocolate and other dishes. The subjects received the consumption of 30 g isomalt or 30 g placebo in food within two daily changing menu plans. By a the influence of other nutritional factors could be excluded from identical basic food in both periods.

Various confectionery and bakery products with isomalt and sugar were made:

At the end of both test phases, the stool was quantitatively collected and, based on the stool samples obtained, the qualitative and quantitative composition of the stool flora and thus also the change in individual bacterial species in relation to the total flora was determined microbiologically. For each subject, the microbial faecal flora without consuming isomalt was compared with the faecal flora when consuming isomalt. In this way, differences and changes due to isomalt consumption could be recorded in each individual.

The analysis of the microbial stool flora was carried out on the one hand using classic microbiological diagnostics in bacteriology by the Use of selective culture media. On the other hand, an independent analysis was carried out using fluorescence in situ hybridization (FISH), a molecular biological methodology with fluorescence-labeled and bacteria-cluster-specific RNA probes.

Microbiological analysis using culture medium technology:

In the bacteriological examinations of the stool samples, different bacterial species were examined, e.g. Bifidobacteria and Bacteroides and Lactobacillus.

The results of the microbiological tests using nutrient media are shown in Table 1 below.

Table 1: Comparison of the bacterial numbers in human stool samples after consumption of 30 g / day isomalt or placebo over four weeks.

The number of bacteria using culture medium technology is given as median (min-max) in cfu (nucleating units = number of bacteria) x 10 ⁸ per g faeces; Level of significance: *** p ≤0.01

The bifidogenic effect of isomalt was determined from a comparison of the bifidobacteria in stool samples for all subjects in the study without isomalt consumption compared to stool samples when isomalt consumption.

The results from the microbiological stool examinations show for the anaerobic indicator flora that significantly more bifidobacteria were present in stool samples with isomalt consumption. On average, the number of bifidobacteria in stool samples with isomalt consumption per day was more than twice as high.

Microbiological analysis with FISH:

For the 16S-RNA, specific and fluorescence-labeled probes were used to detect bifidobacteria and the total number of bacteria (Eubacterium cluster) in stool samples using the FISH method (Kleessen et al. (2001), Br. J. Nutr. 86, 291-300; Schwiertz et al. (2000), Appl. Environ. Microbiol. 66, 375-381).

The results from the FISH analysis are shown in Table 2.

Table 2: Number of bifidobacteria and percentage of bifidobacteria in total bacteria in human stool samples after consumption of 30 g / day isomalt or placebo over four weeks.

The number of bacteria is given as median (min-max) in cfu ((KKeeiimmbbiillddeennddee EEuninnheit = number of bacteria) x 10 ¹¹ ; level of significance: * p <0.05; ** p <0.02

The results of the microbiological examination of the stool samples using the FISH technique revealed significantly more bifidobacteria in stool samples per day with isomalt consumption compared to placebo (10.3 vs 6.9 x 10 ¹¹ bifidobacteria; p ≤ 0.05). The proportion of bifidobacteria in total bacteria in stool samples was around 30% higher with isomalt. In the microbiological tests it was found that consumption of products containing isomalt leads to a significant increase in the number of bifidobacteria in stool samples and the proportion of bifidobacteria in the total flora. Overall, stimulation of the growth of bifidobacteria with isomalt consumption was found in the studies.

These results for increasing the bifidobacteria show an improvement of the intestinal milieu with a particularly positive profile of the microflora by consuming isomalt and thus prove the prebiotic properties of isomalt.

Example 2: Effect of isomalt on the activity of the microbial enzyme β-glucosidase

To demonstrate the effects of isomalt on the intestinal milieu and the influence of intestinal microflora and their activity in humans, the activity of the microbial ß-glucosidase in stool samples was determined in the course of the intervention study shown in Example 1 at the end of the two 4-week test phases. The detection of ß-glucosidase in stool samples was carried out by means of a test for the cleavage of p-nitrophenyl-ß-D-glucopyranoside with the release of p-nitrophenol. The reaction mixture of 1500 μl buffer, 400 μl substrate (0.01 mol / l) and the stool sample was incubated for 1 h at 37 ° C., after 60 min 1 ml stop reagent (glycine buffer 0.1 mol / l pH 12.0) added and the intensity of the resulting yellowing at a wavelength of 405 nm was determined photometrically. The intensity is proportional to the activity of the enzyme. The activity of the enzyme is given as the released product [μmol] per sample [g] per unit of time [h].

As shown in FIG. 1, consumption of isomalt leads to a significant reduction in the overall activity of the microbial β-glucosidase in stool samples. The average before total β-glucosidase activity reduced by 40.3%. The reduction in the microbial β-glucosidase shows that isomalt inhibits the harmful microorganisms and / or inhibits their activity. Since the release of potentially carcinogenic and toxic aglycones is being discussed for the microbial ß-glucosidase, this is regarded as a protective effect for keeping the intestine and the intestinal function healthy.

These results show an improvement in the intestinal milieu with a particularly positive microflora profile due to isomalt and demonstrate the prebiotic properties of isomalt.

Example 3: Degradation of isomalt by bifidobacteria

In vitro studies with pure cultures of bifidobacteria were carried out.

To study the growth of human bifidobacteria, various strains of human bifidobacteria (see below) were first grown on the following medium:

Casein peptone 10 g

Meat extract 5 g

Yeast extract 5 g

Na ₂ HPO ₄ 1.44 g

NaH ₂ PO ₄ 0.24 g

K ₂ HPO ₄ 6.0 g

Tween 80 1.0 g

Cysteine / HCI 0.5 g

Trace element solution after

DSM medium 141 9 ml

Vitamin solution after

DSM medium 141 0.5 ml

Resazurin 1 mg Glucose 10 g

H ₂ O ad 1000 ml, pH 7.0

The individual strains were incubated for 48 hours at 37 ° C. in hunger tubes under anaerobic conditions under an atmosphere of 80% / 20% N ₂ / CO ₂ and then inoculated again on the same nutrient medium. The cultures were then inoculated onto hunger tubes with an identical medium which contained isomalt as the only substrate. After an incubation time of 48 h at 37 ° C., a second transfer to the same medium with isomalt took place.

Cell-free supernatants were prepared from the cultures by centrifugation at 8000 × g for 15 min. The following parameters were examined: residual content isomalt, optical density (OD ₅₇₈ ), lactate, acetate.

Table 3 shows the results of isomalt degradation, growth based on the increase in optical density, and the formation of lactate and acetate.

Table 3: Investigation of the metabolic activity of various human bifidobacteria with isomalt

The results show that isomalt is broken down by bifidobacteria, used for growth and reproduction, and that it can stimulate lactobacteria, especially bifidobacteria, in the intestinal tract.

Example 4: Comparison of the degradation rate of isomalt and fructooligosaccharides during in-fermentation with human intestinal bacteria

A 10% faecal suspension was prepared from stool samples from test subjects under anaerobic conditions in 50 mmol / l phosphate buffer, pH 7.0 and this was used to inoculate the following nutrient medium: Trypton 1.5 g

Yeast extract 1.0 g

KH ₂ PO ₄ 0.24 g

Na ₂ HPO ₄ 0.24 g

(NH ₄ ) ₂ SO ₄ 1, 24 g

NaCI 0.48 g

MgSO ₄ x 7 H ₂ O 0.10 g

CaCl ₂ x 2 H ₂ O 0.06 g

FeSO ₄ x 7 H ₂ O 2 mg

Resazurin 1 mg

Cysteine / HCI 0.5 g

Vitamin solution (according to DSM 141) 0.5 ml

Trace element solution (according to DSM 141) 9.0 ml

NaHCO ₃ 2.0 g

H ₂ O dest. ad 1000 ml, p 7.0

For the cultivation of intestinal bacteria with isomalt or fructooligosaccharides, 9 ml of the anaerobic medium listed was mixed with 0.5% (w / v) of the carbohydrate to be tested and then inoculated with 1 ml of the 10% fecal suspension. Hungate tubes were incubated with shaking at 37 ° C for 28 h, samples were taken at different times and these were examined for the amount of residual carbohydrate.

As can be seen from FIG. 2, the fructooligosaccharides used in in vitro fermentation experiments were completely metabolized within approx. 8 h; in the case of fermentation experiments with isomalt, no carbohydrate was detectable until after 14 h.

During the in vitro fermentation of isomalt, significantly higher concentrations of butyrate were formed (14.2 mmol / l). In the fermentation of fructooligosaccharides, only 2.5 mmol / l butyrate were synthesized (FIG. 3). Isomalt is metabolized more slowly by human intestinal flora and leads to higher butyrate production than fructooligosaccharides.

Example 5: Confectionery

hard candies

Isomalt 375 g

Water 120 g

Citric acid 4 g

Aroma 0.6 g color 0.3 g

Boil isomalt and water in the candy cooker to 155-160 ° C. Vacuum for 5 min under full vacuum. Cool the mass to 110-115 ° C. Addition of acid, aroma, color solution. The melt is stamped or poured.

soft caramels

Isomalt 121 g

Maltitol syrup (75% TS) 256 g

Water 25 g

Gelatin 120 Bloom (40%) 18 g

Vegetable fat (34-36 ° Sp) 29 g

Emulsifier 3.8 g

Citric acid (monohydrate) 3.5 g

Color (10% solution) 0.4 g

Aroma i g

Boil isomalt, maltitol syrup and water to 132-136 ° C (depending on the desired consistency). Add the gelatin solution. Add vegetable fat, emulsifier, citric acid, and color in the order listed and mix at high speed for 2-3 minutes a homogeneous mixture is achieved. Add the aroma and mix, empty the kettle. Homogenize the mass. Cool the mass to 44-46 ° C. Allow the chilled soft caramel mixture to steep for 5-10 minutes (temperature then 47-49 ° C) and process further.

jelly fruits

Isomalt 152 g

Lycasin 235 g

Obipectin Yellow Ribbon 1500 6.5 g

Citric acid krist. monohydr. 2.5 g

Water 100 g

Color 0.5 g

Aroma i g

Mix the pectin dry with approx. 10% isomalt and sprinkle into the cold water while stirring. Bring to the boil and cook until the solution is clear. Add the remaining isomalt and lycasin. Boil down to about 78 ° Brix. Add citric acid dissolved in a little water, add color and aroma and pour into powder boxes.

Example 6: Dog food

dog biscuits

150 g curd

120 g milk

90 g sunflower oil

35 g egg yolk

200 g ground dog flakes

150 g grated cheese

45 g isomalt

Mix the ingredients, form small balls and bake at 200 ° C for about 20 minutes. Dog cookies

150 g whole wheat flour

200 g whole grain oat flakes

5 g granular chicken broth

100 g whole egg

200 g milk

75 g isomalt

Mix the ingredients, roll out the dough, cut out cookies and bake at 220 ° C for about 15 minutes.

Example 7: Prebiotic and Synbiotic Feed Mixtures

Prebiotic feed mix for piglet rearing

Corn 40.00 g

Wheat. 19.51 g

Soybean meal 24.36 g

Protex 5.00 g

Soybean oil 1.00 g

L-lysine 0.34 g

DL-methionine 0.05 g

Vit.-mineral food 2.24 g

Isomalt 7.50 g

Svnbiotic feed mix for piglet rearing

Corn 40.00 g

Wheat 19.51 g

Soybean meal 24.36 g

Protex 5.00 g

Soybean oil 1.00 g

L-lysine 0.34 g

DL-methionine 0.05 g Vit.-mineral food 2.24 g

Probiotic strain 0.01 g e.g. Pediococcus acidilactici

Isomalt 7.50 g

Example 8: Muesli

granola bar

200 g oatmeal

100 g corn flakes

100 g hazelnuts 50 g sunflower seeds

30 g grated coconut

150 g isomalt

150 g honey

50 g butter 20 g lemon juice

20 g water

Caramelize isomalt, honey, butter, lemon juice and water. Mix oatmeal, cornflakes, nuts, sunflower seeds and grated coconut and add. Mix well and spread on a baking sheet. Cut out the bars, pack them and store them in a dry place.

Winter Granola

80 g oatmeal

40 g millet flakes

20 g wheat germ flakes

40 g lemon juice

150 g yogurt

20 g sea buckthorn

50 g chopped nuts 10 g raisins

400 g apples

200 g pears

300 g oranges

150 g bananas

60 g isomalt

Mix flakes, yogurt, sea buckthorn and nuts. Roughly grate the apple, mix with lemon juice and add. Dice the remaining fruits, mix with isomalt and add.

Example 9: Drinks

Power drink

300 g orange juice

30 g wheat germ

15 g isomalt

200 g of yogurt

Whisk the orange juice with wheat germ and isomalt and stir in the yoghurt.

athletes cocktail

250 g carrots 200 g cucumber

200 g tomatoes

250 g apples

100 g cream

10 g parsley 50 g isomalt

Juice carrots, cucumber, tomatoes and apples. Add the cream, parsley and isomalt. tomato cocktail

800 g tomatoes

100 g cream

100 g orange juice

0.5 g salt

10 g isomalt

0.5 g bell pepper

0.5 g tabasco

Puree the tomatoes and mix with the remaining ingredients.

Example 10: Fruit preparations

fruit puree

Berry fruits 230 g

Isomalt 220 g

Binder mix 53 g flavors and, if necessary, color

Puree fruits, bring to the boil, stirring must be carried out during the entire production process. Add isomalt and cook. Mix in the binder mix without lumps. Boil down to max. 75-80% dry matter.

Example 11: Dessert (milk product)

Dessert cream

Isomalt 334 g

Skimmed milk powder 110 g

Corn starch 37 g carageen 13 g Vanilla flavor 5 g

Yellow color 0.05 g

Mix all components well. In a portion of 2500 ml whole milk, stir the powder until smooth. Bring the rest of the milk to the boil. Stir the powder mixture into the boiling milk and bring to the boil. Fill and keep cool until ready to eat.

Example 12: Jam

Südzucker Gelierzucker recipe

Recipe GZ 2 plus 1 g

amidated pectin 6.4 g

Citric acid 3.8 g

Sorbic acid 0.6 g

Isomalt 489.2 g

Fruit quantity 970.0 g

Cooking time 4 minutes each

Sour cherry jam

Isomalt 125 g

Sour cherries 225 g pectin 4.5 g

Citric acid 4.5 g

Calcium citrate 0.5 g

L-ascorbic acid 0.25 g

Sorbic acid 0.25 g water 150 g

Mix the pectin with 1/3 of the isomalt. Heat water with chopped cherries and pectin / isomalt mixture. Just before cooking Add the remaining amount of isomalt and the other ingredients. Cook for two minutes. Filling in jars and lids.

Example 13: Baked goods

Breakfast croissant

Yeast 25.00 g

Cream 300.00 g

Sugar 25.00 g

Isomalt 50.00 g

Wheat flour type 550 400.00 g

Salt 0.15 g

Margarine 200.00 g

Egg yolk 50.00 g

Mix the yeast, lukewarm cream, 1 pinch of salt and 1 pinch of flour. 10 min. let go. Knead with other ingredients and stir for 20 min. let go. Knead the dough, roll it out, cut out 15 triangles and roll up into croissants. Let rise briefly and bake at 200 ° C for 10 minutes.

White bread

Yeast 40.0 g

Sugar 15.0 g

Isomalt 30.0 g

Wheat flour type 550 1000.0 g

Milk 500.0 g

Margarine 250.0 g grated lemon peel 2.5 g

Whole egg 50.0 g Stir yeast with sugar into lukewarm milk and stir for 10 min. let go. Knead with the other ingredients and 20 min. let go. Bake in a bread pan for 45 minutes at 175 ° C.

Sesame bread

Yeast 60.00 g

Milk 500.00 g

Sugar 30.00 g

Isomalt 60.00 g

Wheat flour type 550 300.00 g

Rye flour type 1150 250.00 g

Wheat meal type 1700 200.00 g

Salt 0.15 g

Margarine 100.00 g

Sesame seeds 100.00 g

For production see white bread

hard biscuits

Wheat flour type 550 312 g

Isomalt 78 g

Peanut hard fat

(Melting point approx. 35 ° C) 31 g

Salt 1.5 g

citric acid

(10% aqueous solution) 1.5 g

Milk 70 g

Ammonium bicarbonate 3 g

Sodium bicarbonate 1.5 g

Suspensions of milk, isomalt, salt, citric acid and leavening agent are kneaded with half the flour to a pre-batter. Then make the main dough from pre-batter, fat and remaining flour. Kneading time, pre-dough 7 min, main dough: 13 min, dough resting time: approx. 20 min. Baking temperature: temperature curve of 200 ° C, 300 ° C, 270 ° C. Baking time approx. 6 min when using a continuous oven.

Fine dough without yeast

Recipe: Shortbread wholemeal biscuit

Wheat flour type 550 51, 5 g 25.2 g

Whole Wheat Grain - 25.2 g

Isomalt 15.5 g 20 g

Baking margarine, solid 25.8 g 20.1 g

Salt 0.3 g 0.3 g

Water 6.7 g 9 g

Ammonium bicarbonate 0.2 g 0.2 g

Stir in fat with a third of the flour, then add isomalt, salt and gradually the liquid and continue stirring until the mixture is smooth. Finally, work in the remaining flour. Baking temperature: for example 200 ° C, approx. 9-13 min when using a shooting oven.

Example 14: Dairy products

Yogurt Lemon Shake

600 g lean yogurt

160 g lemon juice

60 g honey

30 g isomalt

120 g egg yolk

Mix ingredients Yogurt cream with raspberries

450 g whole milk yogurt

8 g gelatin

150 g isomalt

20 g lemon juice

20 g whole milk

150 ml cream

300 g raspberries

Soak the gelatin. Mix yogurt, isomalt, lemon juice and whole milk until smooth. Dissolve and add the gelatin. Whip the cream until stiff and pull it into the mixture. Put the raspberries in a bowl and pour the yoghurt mixture on top.

Bibliography:

• Cummings JH, Macfarlane GT, Englyst HN. Prebiotic digestion and fermentation. At the. J. Clin. Nutr. (2001) Feb; 73 (2nd

Suppl): 415S-420S

Caraway, KF & Brokx, S. Lactitol as functional prebiotic. Cereal Foods World (2001), 46, 425-429

• Kashimura, J, Fujisawa, T, Nakajima, Y, Nishio, K, Mitsuoka, T. Utilization of palatinose, palatinose condensates, trehallosose and isomalt by various intestinal bacteria. J. Jpn. Soc. Nutr. Food. Be. (1991), 44, 54-59.

Filler R. Probiotics in man and animals. J Appl. Bacteriol. 1989, 66: 365-378

• Kleessen B, Hartmann L, Blaut M. Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats as- soeiated with a human faecal flora. Br. J. Nutr. (2001), 86 (2): 291-300.

Schwiertz A, Le Blay G, Blaut M. Quantification of different Eubacterium spp. in human fecal samples with species-specific 16S rRNA-targeted oligonucleotide probes. Appl. Environ. Microbiol. (2000), 66 (1): 375-82.

Claims

Expectations

1. Use of a mixture of 6-O-α-D-glucopyranosyl-D-sorbitol (1, 6-GPS) and 1-O- -D-glucopyranosyl-D-mannitol (1, 1-GPM) as a prebiotic.

2. Use according to claim 1 as a bifidogenic prebiotic.

3. Use according to claim 1 as a butyrogenic substrate with properties of soluble fiber.

4. Use according to claim 1 as a substance with properties of fiber and fiber and / or indigestible carbohydrates.

5. Use according to claim 1 as a substance with prebiotic properties.

6. Use according to any one of the preceding claims, wherein the mixture is used in a food, luxury food or feed.

7. Use according to any one of the preceding claims, wherein the mixture is the only butyrogenic substrate.

8. Use according to one of the preceding claims, wherein the mixture is the only prebiotic, in particular bifidogenic prebiotic, in the food, luxury food, feed or pharmaceutical.

9. Use according to one of the preceding claims, wherein the mixture is isomalt.

10. Use according to one of the preceding claims, wherein the mixture contains 1-O-α-D-glucopyranosyl-D-sorbitol (1, 1 -GPS).

Ii n

11. Use according to one of the preceding claims, wherein the mixture contains mannitol, sorbitol, hydrogenated and / or non-hydrogenated oligosaccharides.

12. Use according to one of the preceding claims, wherein the mixture has at least one further prebiotic.

13. Use according to one of the preceding claims, wherein the mixture, in particular in addition to isomalt, contains at least one further dietary fiber and / or indigestible carbohydrate.

14. Use according to one of the preceding claims, wherein the fiber is an oligosaccharide or polysaccharide, such as fructo-

Oligosaccharide, polydextrose, xyloarabane, inulin, a galacto-oligosaccharide, lactulose, lactitol, a xylo-oligosaccharide, lacto-sucrose, a malto-oligosaccharide, an isomalto-oligosaccharide, a gentio-oligosylsaccharide, a gentio-oligosylsaccharide, a gentio-oligosaccharide, -Oligosaccharide, a chitosan oligosaccharide, a pectin, a condensed oligosaccharide, a caramel product, a galactomannan oligosaccharide, a fucose-containing oligosaccharide, a fucose derivative-containing oligosaccharide, modified starch, partially hydrolyzed mannitol, guar gum, x , Erythritol, hydrogenated starch hydrolyzate, pyrodextrin or a variant obtained by partial hydrolysis, hydrogenation, oxidation, enzymatic, chemical or other modification of saccharides.

15. Use according to one of the preceding claims, wherein the insoluble fiber-resistant starch and / or fiber material

Wheat, oat, tomato, bean, which is the fruit of the carob tree, sugar beet or cellulose.

16. Use according to any one of the preceding claims, wherein the mixture contains at least one indigestible carbohydrate.

Λl-

17. Use according to one of the preceding claims, wherein the mixture contains at least one probiotic.

18. Use according to any one of the preceding claims, wherein the probiotic is derived from the genus Lactobacillus and / or Bifidobacterium.

19. Use according to one of the preceding claims, wherein the mixture is present as a synbiotic.

20. Use according to one of the preceding claims, wherein the mixture is present in solid form in the food, luxury food, feed or pharmaceutical.

21. Use according to one of the preceding claims, wherein the mixture is present in the food, luxury food, feed or medicament suspended or dissolved in water.

22. Use according to one of the preceding claims for the production of a food, luxury food or feed.

23. Use according to one of the preceding claims for the manufacture of a medicament.

24. Use according to claim 23 for the manufacture of a medicament for the treatment and / or prevention of intestinal diseases.

25. Use according to claim 23 for the manufacture of a medicament for restoring and / or stabilizing a healthy intestinal flora.

26. Use according to claim 23 for the manufacture of a medicament for maintaining a healthy intestinal epithelium.

-4P-

27. Use according to claim 23 for the manufacture of a medicament for supporting intestinal health.

28. Use according to claim 23 for the manufacture of a medicament for restoring and / or promoting a healthy intestinal flora metabolism.

29. Use according to claim 23 for the manufacture of a medicament for reducing toxic and damaging intestinal contents.

30. Use according to claim 23 for the manufacture of a medicament for reducing oxidative stress.

31. Use according to claim 23 for the manufacture of a medicament for the prevention and / or treatment of inflammatory bowel diseases.

32. Use according to claim 23 for the manufacture of a medicament for the prevention of colon cancer, in particular colon cancer.

33. Use according to claim 23 for the manufacture of a medicament for the prophylaxis and / or treatment of infectious diseases, in particular bacterial intestinal infections and diarrhea

34. Use according to claim 23 for the manufacture of a medicament for modulating and strengthening the immune system.

35. Use according to one of the preceding claims, wherein the food, luxury food or feed is a milk product or a milk product such as cheese, butter, yogurt, drinking yoghurt, kefir, curd cheese, sour milk, buttermilk, cream , Condensed milk, dry milk, whey, milk sugar, milk protein, milk mix, milk semi-fat, whey mix, or milk fat product or - Preparation; a baked good, in particular bread, rolls, croissant including small baked goods or fine baked good including long-life baked goods, biscuit product or waffle; a spread; Margarine product; Shortening; an instant product; Brüherzeugnis; a fruit product; a fruit preparation such as jam, jam, jelly, canned fruit, fruit pulp, fruit pulp, fruit juice, fruit concentrate, fruit nectar or fruit powder; a vegetable product or preparation such as canned vegetables, vegetable juice or vegetable pulp; a spice mix; a cereal or a cereal mixture; a product containing a prepared muesli; a non-alcoholic drink such as athletic drink and diet lemonade; Beverage base; Powdered drinks; a confectionery such as chocolate, hard caramel, soft caramel, chewing gum, dragee, fondant product, jelly product, licorice, sparkling sugar, flakes, dragee, compressed fruit, candied fruit, brittle, nougat product, ice confection, marzipan, cereal bars, ice cream, alcoholic and non-alcoholic sweet drink; enteral diet or animal feed.

36. Use according to one of the preceding claims for the treatment and / or prevention of intestinal diseases.

37. Use according to one of the preceding claims for restoring and / or stabilizing a healthy intestinal flora.

38. Use according to one of the preceding claims for maintaining a healthy intestinal epithelium.

39. Use according to one of the preceding claims to support intestinal health.

40. Use according to one of the preceding claims for restoring and / or promoting a healthy intestinal flora metabolism.

41. Use according to one of the preceding claims for the reduction of toxic and damaging intestinal contents.

42. Use according to one of the preceding claims for reducing oxidative stress.

43. Use according to one of the preceding claims for the prevention and / or treatment of inflammatory bowel diseases.

44. Use according to one of the preceding claims for the prevention of colon cancer, in particular colon cancer.

45. Use according to one of the preceding claims for the prophylaxis and / or treatment of. Infectious diseases, especially bacterial intestinal infections and diarrhea

46. Use according to one of the preceding claims for modulating and strengthening the immune system.